Religare Research has come out with its first quarter (April-June) earnings estimates for the India Pharmaceuticals sector. The brokerage house expects Cadila HC to report a degrowth of 8.8 percent quarter-on-quarter (up of 0.3 percent year-on-year) in net profit at Rs 354.6 crore. Sales are expected to increase by 0.2 percent Q-o-Q (down 1.9 percent Y-o-Y) to Rs 2453.8 crore, according to Religare Research. Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 8.7 percent Q-o-Q (down 11.7 percent Y-o-Y) to Rs 531.0 crore. Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.